NVO - Anti-Counterfeiting Group Identifies Fake Diabetes Drug Ozempic in 16 Countries: Sparks Patient Harm Concerns | Benzinga
In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic (semaglutide), Novo Nordisk A/S’s (NYSE:NVO) CEO, Lars Fruergaard Jorgensen, reportedly affirmed the company is collaborating with authorities across multiple countries.
Jorgensen emphasized the gravity of the situation, stating, “This is something we take very seriously.”
The surge in demand for Novo’s drugs, particularly those promoting weight loss, has outpaced supply, raising concerns about unregulated and counterfeit medicines globally.
The Partnership for Safe Medicines, an anti-counterfeiting group, has identified counterfeit Ozempic in 16 countries.
Disturbing reports obtained through Freedom of Information Act (FOIA) requests indicate patient harm ...